These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30030074)

  • 1. Current status of G-protein coupled receptors as potential targets against type 2 diabetes mellitus.
    Hoque M; Ali S; Hoda M
    Int J Biol Macromol; 2018 Oct; 118(Pt B):2237-2244. PubMed ID: 30030074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. G-protein-coupled receptors (GPCRs) in the treatment of diabetes: Current view and future perspectives.
    Sebastiani G; Ceccarelli E; Castagna MG; Dotta F
    Best Pract Res Clin Endocrinol Metab; 2018 Apr; 32(2):201-213. PubMed ID: 29678286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G protein-coupled receptors as therapeutic targets for obesity and type 2 diabetes.
    Bjenning C; Al-Shamma H; Thomsen W; Leonard J; Behan D
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1051-62. PubMed ID: 15535426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G protein-coupled receptors as new therapeutic targets for type 2 diabetes.
    Reimann F; Gribble FM
    Diabetologia; 2016 Feb; 59(2):229-33. PubMed ID: 26661410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An atlas and functional analysis of G-protein coupled receptors in human islets of Langerhans.
    Amisten S; Salehi A; Rorsman P; Jones PM; Persaud SJ
    Pharmacol Ther; 2013 Sep; 139(3):359-91. PubMed ID: 23694765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Islet G-protein coupled receptors: therapeutic potential for diabetes.
    Persaud SJ
    Curr Opin Pharmacol; 2017 Dec; 37():24-28. PubMed ID: 28822846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. G Protein-Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus.
    Riddy DM; Delerive P; Summers RJ; Sexton PM; Langmead CJ
    Pharmacol Rev; 2018 Jan; 70(1):39-67. PubMed ID: 29233848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges.
    Li Z; Xu X; Huang W; Qian H
    Med Res Rev; 2018 Mar; 38(2):381-425. PubMed ID: 28328012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic Functions of G Protein-Coupled Receptors in Hepatocytes-Potential Applications for Diabetes and NAFLD.
    Kimura T; Pydi SP; Pham J; Tanaka N
    Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33076386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes.
    Ahrén B
    Nat Rev Drug Discov; 2009 May; 8(5):369-85. PubMed ID: 19365392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of novel ligands for peptide GPCRs.
    Moran BM; McKillop AM; O'Harte FP
    Curr Opin Pharmacol; 2016 Dec; 31():57-62. PubMed ID: 27607913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. G protein-coupled receptors as regulators of glucose homeostasis and therapeutic targets for diabetes mellitus.
    Tao YX; Liang XF
    Prog Mol Biol Transl Sci; 2014; 121():1-21. PubMed ID: 24373233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G Protein-Coupled Receptor (GPCR) Expression in Native Cells: "Novel" endoGPCRs as Physiologic Regulators and Therapeutic Targets.
    Insel PA; Wilderman A; Zambon AC; Snead AN; Murray F; Aroonsakool N; McDonald DS; Zhou S; McCann T; Zhang L; Sriram K; Chinn AM; Michkov AV; Lynch RM; Overland AC; Corriden R
    Mol Pharmacol; 2015 Jul; 88(1):181-7. PubMed ID: 25737495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G protein-coupled receptors as promising cancer targets.
    Liu Y; An S; Ward R; Yang Y; Guo XX; Li W; Xu TR
    Cancer Lett; 2016 Jul; 376(2):226-39. PubMed ID: 27000991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146.
    Kolar GR; Grote SM; Yosten GL
    J Intern Med; 2017 Jan; 281(1):25-40. PubMed ID: 27306986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting lipid GPCRs to treat type 2 diabetes mellitus - progress and challenges.
    Ghislain J; Poitout V
    Nat Rev Endocrinol; 2021 Mar; 17(3):162-175. PubMed ID: 33495605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances in Development of GPR40 Modulators (FFA1/FFAR1): An Emerging Target for Type 2 Diabetes.
    Sharma N; Bhagat S; Chundawat TS
    Mini Rev Med Chem; 2017; 17(11):947-958. PubMed ID: 28117025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental challenges to targeting poorly characterized GPCRs: uncovering the therapeutic potential for free fatty acid receptors.
    Hudson BD; Smith NJ; Milligan G
    Adv Pharmacol; 2011; 62():175-218. PubMed ID: 21907910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GPR40 agonists for the treatment of type 2 diabetes mellitus: The biological characteristics and the chemical space.
    Chen C; Li H; Long YQ
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5603-5612. PubMed ID: 27825762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into unbound-bound states of GPR142 receptor in a membrane-aqueous system using molecular dynamics simulations.
    Kaushik AC; Sahi S
    J Biomol Struct Dyn; 2018 May; 36(7):1788-1805. PubMed ID: 28571491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.